Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Longeveron Inc (NQ: LGVN ) 3.900 +0.380 (+10.80%) Streaming Delayed Price Updated: 4:00 PM EDT, Jul 17, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Longeveron Inc < Previous 1 2 3 4 5 6 7 8 9 ... 14 15 Next > As America Grapples With A Deadly Opioid Epidemic, BioRestorative Therapies Is Looking To Treat Chronic Pain Without The Need For Class-A Drugs August 29, 2023 Chronic back pain is a significant issue in the United States, affecting millions of individuals annually. According to experts, up to 80% of the population will experience back pain at some point. Via Benzinga Earnings Scheduled For August 11, 2023 August 11, 2023 Companies Reporting Before The Bell • Consolidated Water Co (NASDAQ:CWCO) is estimated to report quarterly earnings at $0.22 per share on revenue of $30.27 million. Via Benzinga Earnings Preview: Longeveron August 10, 2023 Via Benzinga Longeveron Announces Key Additions To Its Leadership Team and Board As It Gears Up For Phase 2 Trials For Its Lead Drug Candidate For Several Conditions August 08, 2023 By David Willey, Benzinga Via TheNewswire.com LGVN Stock Earnings: Longeveron Misses EPS, Revenue Estimates May 12, 2023 LGVN stock earnings show Longeveron reporting a wider loss than analysts expected and missing revenue estimates. Via InvestorPlace Recap: Longeveron Q1 Earnings May 12, 2023 Via Benzinga Preview: Longeveron's Earnings May 11, 2023 Via Benzinga Longeveron Announces Key Additions To Its Leadership Team and Board As It Gears Up For Phase 2 Trials For Its Lead Drug Candidate For Several Conditions August 08, 2023 --News Direct-- Via News Direct Longeveron – This Biotech Company Is Using The Body's Own Cells To Fight Age-Related Diseases August 07, 2023 Wa'el Hashad, CEO of Longeveron (NASDAQ: LGVN), was recently interviewed by Benzinga. Via Benzinga Longeveron Announces Key Additions To Its Leadership Team And Board As It Gears Up For Phase 2 Trials For Its Lead Drug Candidate For Several Conditions August 07, 2023 Longeveron, Inc. (NASDAQ: LGVN) is a clinical-stage biopharmaceutical company focused on therapies for age-related and life-threatening diseases. Via Benzinga Longeveron – Regenerative Medicine Developer Announces 100% Long Term Survival Rate For Children With HLHS July 11, 2023 Hypoplastic left heart syndrome, or HLHS, has a historical mortality rate of 20% within five years of diagnosis. The disease affecting children may have a new therapy in Longeveron’s (NASDAQ: LGVN)... Via Benzinga 12 Health Care Stocks Moving In Friday's Pre-Market Session July 07, 2023 Via Benzinga HLHS Is A Rare And Serious Congenital Heart Disease With A 33% Neonatal Death Rate — Could Longeveron’s Lomecel-B Improve Outcomes? July 07, 2023 HLHS Is A Rare And Serious Congenital Heart Disease With A 33% Neonatal Death Rate — Could Longeveron’s Lomecel-B Improve Outcomes? Via News Direct Exposures Product Safety HLHS Is A Rare And Serious Congenital Heart Disease With A 33% Neonatal Death Rate — Could Longeveron’s Lomecel-B Improve Outcomes? July 07, 2023 By David Willey, Benzinga Via TheNewswire.com Exposures Product Safety HLHS Is A Rare And Serious Congenital Heart Disease With A 33% Neonatal Death Rate — Could Longeveron's Lomecel-B Improve Outcomes? June 28, 2023 Longeveron (NASDAQ: LGVN) announced the results of its phase 1 trial for infants with a rare and serious congenital heart disease (CHD), known as hypoplastic left heart syndrome. Via Benzinga Earnings Scheduled For May 12, 2023 May 12, 2023 Companies Reporting Before The Bell • Honda Motor Co (NYSE:HMC) is expected to report earnings for its fourth quarter. Via Benzinga Longeveron's Lomecel-BTM Shows Encouraging Survival Data, Keeps Hypoplastic Left Heart Syndrome Pediatric Patients Heart Transplant-Free May 09, 2023 Longeveron Inc (NASDAQ: LGVN) announced new long-term follow-up data from its ELPIS I trial of Lomecel-BTM for patients with Via Benzinga 12 Health Care Stocks Moving In Tuesday's Intraday Session May 09, 2023 Via Benzinga Why PRA Group Shares Are Trading Lower By 44%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session May 09, 2023 Gainers TScan Therapeutics, Inc. (NASDAQ: TCRX) shares gained 118% to $4.68 after the company and Amgen announced collaboration to identify novel targets in Crohn's disease. Via Benzinga Why Is Longeveron (LGVN) Stock Up 30% Today? May 09, 2023 Longeveron (LGVN) stock is on the move Tuesday after releasing new long-term survival data from HLHS treatment Lomecel-B. Via InvestorPlace Longeveron Doses First Patient In Phase 2 Clinical Trial Of Lomecel-B™ In Japan For Aging-Related Frailty April 20, 2023 Longeveron Inc. (NASDAQ: LGVN) announced that the first patient has been treated with Lomecel-BTM in its Phase 2 clinical trial in patients with Aging-Related Frailty in Japan. The trial aims to enroll... Via Benzinga Stocks That Hit 52-Week Lows On Tuesday March 21, 2023 On Tuesday, 74 companies achieved new lows for the year. Via Benzinga Earnings Scheduled For March 10, 2023 March 10, 2023 Companies Reporting Before The Bell • CSI Compressco (NASDAQ:CCLP) is estimated to report earnings for its fourth quarter. • Longeveron (NASDAQ:LGVN) is expected to report earnings for its fourth... Via Benzinga Insiders Just Bought $1 Million of This Deep Value Tech Stock March 07, 2023 CEO and CFO buying is a bullish indicator... and based on new SEC filings, things are heating up for IHRT stock. Dive in here. Via InvestorPlace 3 Penny Stocks That Could Rise 500% in 2023 January 13, 2023 Tilt the odds in your favor in 2023 with some of these high-potential penny stocks. The risks are high, but so are the rewards. Via InvestorPlace Longeveron Shares Surge Following FDA Decision on Biogen Alzheimer's Drug January 06, 2023 Shares of Longeveron (NASDAQ: LGVN) are trading 5.37% higher amid strength in Alzheimer's-related stocks after the FDA granted accelerated approval to Biogen (NASDAQ: BIIB)'s Leqembi. Via Benzinga Elon Musk Is a Genius Market Timer. That’s Bad News for Tesla (TSLA) Stock. December 19, 2022 Elon Musk is great at timing the market. He's selling TSLA stock now, and savvy investors would be wise to follow suit. Via InvestorPlace Why Quotient Shares Are Trading Lower By More Than 48%; Here Are 37 Stocks Moving Premarket December 13, 2022 Gainers Netcapital Inc. (NASDAQ: NCPL) shares rose 91.3% to $2.65 in pre-market trading following Q2 results. Netcapital posted Q2 earnings of $0.04 per share on sales of $1.78 million. Via Benzinga How to Find Stocks That Rise 10x October 10, 2022 Investors looking for 10X stocks should prioritize companies in high-growth areas that demonstrate high earnings quality. Via InvestorPlace Insider Buying 2022: 15 Stocks to Bet On Despite the Bear Market October 05, 2022 Following insider buying is a savvy way for retail investors to profit even when a bear market is raging on Wall Street. Here are 15 stocks. Via InvestorPlace < Previous 1 2 3 4 5 6 7 8 9 ... 14 15 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.